1. Dendritic cell profiles in the inflamed colonic mucosa predict the responses to tumor necrosis factor alpha inhibitors in inflammatory bowel diseaseNataša Smrekar, David Drobne, Lojze Šmid, Ivan Ferkolj, Borut Štabuc, Alojz Ihan, Andreja Nataša Kopitar, 2018, izvirni znanstveni članek Povzetek: Background Dendritic cells play crucial roles in the control of inflammation and immune tolerance in the gut. We aimed to investigate the effects of tumor necrosis factor alpha (TNFa) inhibitors on intestinal dendritic cells in patients with inflammatory bowel disease and the potential role of intestinal dendritic cells in predicting the response to treatment. Patients and methods Intestinal biopsies were obtained from 30 patients with inflammatory bowel disease before and after treatment with TNFa inhibitors. The proportions of lamina propria dendritic cell phenotypes were analysed using flow cytometry. Disease activity was endoscopically assessed at baseline and after the induction treatment. Results At baseline, the proportion of conventional dendritic cells was higher in the inflamed mucosa (7.8%) compared to the uninflamed mucosa (4.5%) (p = 0.003), and the proportion of CD103+ dendritic cells was lower in the inflamed mucosa (47.1%) versus the uninflamed mucosa (57.3%) (p = 0.03). After 12 weeks of treatment, the proportion of conventional dendritic cells in the inflamed mucosa decreased from 7.8% to 4.5% (p = 0.014), whereas the proportion of CD103+ dendritic cells remained unchanged. Eighteen out of 30 (60%) patients responded to their treatment by week 12. Responders had a significantly higher proportion of conventional dendritic cells (9.16% vs 4.4%, p < 0.01) with higher expression of HLA-DR (median fluorescent intensity [MFI] 12152 vs 8837, p = 0.038) in the inflamed mucosa before treatment compared to nonresponders. Conclusions A proportion of conventional dendritic cells above 7% in the inflamed inflammatory bowel disease mucosa before treatment predicts an endoscopic response to TNFa inhibitors. Ključne besede: inflammatory bowel disease, dendritic cells, colon cancer Objavljeno v DiRROS: 02.07.2024; Ogledov: 267; Prenosov: 144 Celotno besedilo (909,08 KB) Gradivo ima več datotek! Več... |
2. Slovenska priporočila za obravnavo odraslih bolnikov s kronično odpovedjo prebavilNada Rotovnik-Kozjek, Tajda Božič, Katja Kogovšek, Borut Štabuc, Laura Petrica, Karla Berlec, Nataša Puzić Ravnjak, Erik Brecelj, Aleš Tomažič, Sanela Banović, Rada Franko, Milena Kovač-Blaž, Janez Breznik, Davorin Ćeranić, David Drobne, Mojca Gašperin, Tomaž Jurca, Maja Ebert Moltara, Rado Janša, Marjana Turk Jerovšek, Taja Jordan, Tina Kamhi, Primož Karner, Milena Kerin-Povšič, Neža Majdič, Denis Mlakar-Mastnak, Andreja Ocepek, Tadeja Pintar, Stojan Potrč, Nataša Smrekar, Monika Sonc, Maja Šeruga, Petra Tavčar, Igor Virant, 2021, strokovni članek Ključne besede: kronična odpoved prebavil, zdravljenje, onkološko zdravljenje Objavljeno v DiRROS: 11.06.2021; Ogledov: 1731; Prenosov: 429 Celotno besedilo (135,03 KB) |